Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | S1PR4 | O95977 | 2/20 | 0.44 |
| ▸ | S1PR1 | P21453 | 2/20 | 0.44 |
| ▸ | S1PR3 | Q99500 | 2/20 | 0.44 |
| ▸ | NAAA | Q02083 | 2/20 | 0.41 |
| ▸ | EPHX1 | P07099 | 3/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4585674 | 0.94 | GAA (0.44) | GAAMAPK1HTTSMN1; SMN2S1PR4 | |
| SCHEMBL4719490 | 0.78 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL13387564 | 0.78 | GAA (0.59) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL16526220 | 0.76 | GAA (0.66) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL30581344 | 0.76 | GAA (0.51) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL16146100 | 0.75 | GAA (0.54) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL16544772 | 0.75 | GAA (0.68) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL10793711 | 0.75 | GAA (0.68) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL27688528 | 0.74 | GAA (0.50) | GAAMAPK1HTTSMN1; SMN2NAAA | |
| SCHEMBL30827617 | 0.74 | GAA (0.50) | GAAMAPK1HTTSMN1; SMN2NAAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1458669-A4 | NEUOROLOGICALLY-ACTIVE COMPOUNDS | UNIV SYDNEY (AU) | 2008-10-29 | — | — | EP | disclosed |
| US-6962907-B2 | Neurologically-active compounds | THE UNIVERSITY OF SYDNEY (AU) | 2005-11-08 | — | — | US | disclosed |
| US-20050004083-A1 | Neurologically-active compounds | NEURO THERAPEUTICS LIMITED (AU) | 2005-01-06 | — | — | US | disclosed |
| EP-1458669-A1 | NEUOROLOGICALLY-ACTIVE COMPOUNDS | THE UNIVERSITY OF SYDNEY (AU) | 2004-09-22 | — | — | EP | disclosed |
| WO-2003045897-A1 | NEOROLOGICALLY-ACTIVE COMPOUNDS | UNIVERSITY OF SYDNEY (AU) | 2003-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004083-A1 | Neurologically-active compounds | GABRA2, GABRA5, GABRE | GAA 1636/4885MAPK1 777/4885HTT 733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.